文献速递临床试验与 GCP真实世界研究与卫生经济

通过移动医疗和社区卫生工作者主导的干预措施改善喀拉拉邦心血管疾病患者的用药依从性:II型效果-实施研究方案(SHRADDHA-ENDIRA)

Improving medication adherence among persons with cardiovascular disease through m-health and community health worker-led interventions in Kerala; protocol for a type II effectiveness-implementation research-(SHRADDHA-ENDIRA).
PubMed 文献 · Trials · 2024-07-02

该研究为2×2析因设计的整群随机对照试验,在印度喀拉拉邦18个分中心区域比较ASHA主导的家访干预与移动医疗提醒干预单独及联合使用与标准护理对心血管疾病患者用药依从性的效果,每臂计划样本量393人,并嵌套卫生经济学评价和过程评价。

要点

  • 试验采用2×2析因整群随机设计,以分中心为整群单位,1:1分配至四种实验条件之一。
  • 每臂样本量计算为393人,每臂包含4-5个分中心,共涉及18个分中心区域。
  • 嵌套卫生经济学评价评估干预措施的成本效果和投资回报率,过程评价涵盖可接受性、采纳、适当性、成本、可行性、保真度、渗透性和可持续性。

核心结论

  • 该试验将评估ASHA主导干预和移动医疗干预单独及联合使用对心血管疾病患者用药依从性的效果,并探索本地知识与认知,通过将用药依从性的责任转移至患者自身来赋权患者。

研究设计与样本

  • 研究为2×2析因设计的整群随机对照试验,以分中心为整群单位,1:1分配至四种实验条件:ASHA主导干预、移动医疗干预、两者联合、标准护理。
  • 样本量计算为每臂393人,每臂包含4-5个分中心,共涉及18个分中心区域。
  • 试验嵌套卫生经济学评价以评估干预措施的成本效果和投资回报率,并进行过程评价。

临床怎么用

  • 该方案与WHO非传染性疾病目标一致,即改善可负担的基本技术和基本药物的可及性、培训卫生人力并加强初级保健层面控制非传染性疾病的能力。
  • 该方案还助于扩大数字技术的使用,以提高非传染性疾病治疗的卫生服务可及性和有效性,并可能有助于降低治疗成本。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular disease (CVD) is the leading cause of mortality worldwide, and at present, India has the highest burden of acute coronary syndrome and ST-elevation myocardial infarction (MI). A key reason for poor outcomes is non-adherence to medication. METHODS: The intervention is a 2 × 2 factorial design trial applying two interventions individually and in combination with 1:1 allocation ratio: (i) ASHA-led medication adherence initiative comprising of home visits and (ii) m-health intervention using reminders and self-reporting of medication use. This design will lead to four potential experimental conditions: (i) ASHA-led intervention, (ii) m-health intervention, (iii) ASHA and m-health intervention combination, (iv) standard of care. The cluster randomized trial has been chosen as it randomizes communities instead of individuals, avoiding contamination between participants. Subcenters are a natural subset of the health system, and they will be considered as the cluster/unit. The factorial cluster randomized controlled trial (cRCT) will also incorporate a nested health economic evaluation to assess the cost-effectiveness and return on investment (ROI) of the interventions on medication adherence among patients with CVDs. The sample size has been calculated to be 393 individuals per arm with 4-5 subcenters in each arm. A process evaluation to understand the effect of the intervention in terms of acceptability, adoption (uptake), appropriateness, costs, feasibility, fidelity, penetration (integration of a practice within a specific setting), and sustainability will be done. DISCUSSION: The effect of different types of intervention alone and in combination will be assessed using a cluster randomized design involving 18 subcenter areas. The trial will explore local knowledge and perceptions and empower people by shifting the onus onto themselves for their medication adherence. The proposal is aligned to the WHO-NCD aims of improving the availability of the affordable basic technologies and essential medicines, training the health workforce and strengthening the capacity of at the primary care level, to address the control of NCDs. The proposal also helps expand the use of digital technologies to increase health service access and efficacy for NCD treatment and may help reduce cost of treatment. TRIAL REGISTRATION: The trial has been registered with the Clinical Trial Registry of India (CTRI), reference number CTRI/2023/10/059095.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Menon JC, John D, Sreedevi A, et al. Improving medication adherence among persons with cardiovascular disease through m-health and community health worker-led interventions in Kerala; protocol for a type II effectiveness-implementation research-(SHRADDHA-ENDIRA). Trials. 2024. PMID: 38956612. doi:10.1186/s13063-024-08244-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。